Purple Biotech to Showcase CAPTN-3 Platform at EACR 2025 Congress
PorAinvest
miércoles, 4 de junio de 2025, 1:53 pm ET1 min de lectura
PPBT--
The abstract, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, Vice President of Research and Development at Purple Biotech. The abstract will be available online following the presentation [1].
Purple Biotech focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a novel target for multiple cancer indications. NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [1].
The CAPTN-3 platform is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response [1].
The company's corporate headquarters are located in Rehovot, Israel. For more information, please visit the official website of Purple Biotech [1].
References:
[1] https://www.globenewswire.com/news-release/2025/06/04/3093432/0/en/Purple-Biotech-Announces-Poster-Presentation-at-EACR-2025-on-its-Novel-CAPTN-3-Tri-Specific-Antibody-Platform.html
Purple Biotech will present a poster on its CAPTN-3 tri-specific antibody platform at EACR 2025. The presentation is scheduled for June 17, 2025, during the Immunotherapy session in Lisbon, Portugal. The abstract will be published online post-presentation. Purple Biotech is a clinical-stage biopharmaceutical company focusing on overcoming tumor immune evasion and drug resistance through its developmental therapies.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company, has announced that it will present a poster on its novel CAPTN-3 tri-specific antibody platform at the European Association for Cancer Research (EACR) 2025. The presentation is scheduled for June 17, 2025, during the Immunotherapy session in Lisbon, Portugal.The abstract, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be presented by Dr. Hadas Reuveni, Vice President of Research and Development at Purple Biotech. The abstract will be available online following the presentation [1].
Purple Biotech focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, a novel target for multiple cancer indications. NT219 is a dual inhibitor targeting IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) [1].
The CAPTN-3 platform is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response [1].
The company's corporate headquarters are located in Rehovot, Israel. For more information, please visit the official website of Purple Biotech [1].
References:
[1] https://www.globenewswire.com/news-release/2025/06/04/3093432/0/en/Purple-Biotech-Announces-Poster-Presentation-at-EACR-2025-on-its-Novel-CAPTN-3-Tri-Specific-Antibody-Platform.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios